Please login to the form below

Not currently logged in
Email:
Password:

Blincyto

This page shows the latest Blincyto news and features for those working in and with pharma, biotech and healthcare.

So far so good for Amgen's much-anticipated KRAS inhibitor

So far so good for Amgen's much-anticipated KRAS inhibitor

Amgen will also present data on a clutch of bispecific T-cell engager (BiTE) antibodies at ASCO, as it tries to build a pipeline behind its approved bispecific Blincyto (blinatumomab) for

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen, has had success with in-house bispecifics already, such as acute lymphoblastic leukaemia (ALL) treatment, Blincyto; the in-developme nt acute myeloid leukaemia (AML) therapy AMG 330; and multiple myeloma

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics